TJU103
TJU103 is a CD4 inhibitor. TJU103 inhibits autoreactive CD4+ T cells by disrupting the function of the CD4 during activation. TJU103 decreases mononuclear cell infiltration in brain and spinal cord tissue of experimental allergic encephalomyelitis (EAE) mice model. TJU103 downregulates Th1 and Th2 cytokine levels in response to proteolipid protein epitope 139-151 (PLPe) and exhibits inhibitory effects both after the appearance of EAE symptoms and upon rechallenge with Ag. TJU103 can be used for autoimmune diseases like EAE and sclerosis (MS) research.
For research use only. We do not sell to patients.
- CAS No.: 10245-44-0
- Formula: C15H12N4O
- Molecular Weight:264.28
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEL | EC50 |
>100 μg/mL
Compound: 8
|
Antiviral activity against Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| HEL | EC50 |
>100 μg/mL
Compound: 8
|
Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| HEL | EC50 |
>100 μg/mL
Compound: 8
|
Antiviral activity against TK(-) aciclovir-resistant Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against TK(-) aciclovir-resistant Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| HEL | EC50 |
>100 μg/mL
Compound: 8
|
Antiviral activity against Vaccinia virus infected human HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Vaccinia virus infected human HEL cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| HeLa | EC50 |
>100 μg/mL
Compound: 8
|
Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| HeLa | EC50 |
>100 μg/mL
Compound: 8
|
Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| HeLa | EC50 |
>100 μg/mL
Compound: 8
|
Antiviral activity against Vesicular stomatitis virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Vesicular stomatitis virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| MT4 | CC50 |
95 μg/mL
Compound: 8
|
Cytotoxicity against Homo sapiens (human) MT4 cells
Cytotoxicity against Homo sapiens (human) MT4 cells
|
10.1007/s00044-011-9662-9 |
| MT4 | EC50 |
>95 μg/mL
Compound: 8
|
Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| MT4 | EC50 |
>95 μg/mL
Compound: 8
|
Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| Vero | EC50 |
>100 μg/mL
Compound: 8
|
Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| Vero | EC50 |
>100 μg/mL
Compound: 8
|
Antiviral activity against Punta Toro virus infected Vero cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Punta Toro virus infected Vero cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| Vero | EC50 |
>100 μg/mL
Compound: 8
|
Antiviral activity against Sindbis virus infected Vero cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Sindbis virus infected Vero cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| Vero | EC50 |
2.4 μg/mL
Compound: 8
|
Antiviral activity against Mammalian orthoreovirus 1 infected Vero cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Mammalian orthoreovirus 1 infected Vero cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| Vero | EC50 |
45 μg/mL
Compound: 8
|
Antiviral activity against Human coxsackievirus B4 infected Vero cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Human coxsackievirus B4 infected Vero cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
Chemical Information
-
CAS No. 10245-44-0
-
Molecular Weight 264.28
-
Formula C15H12N4O
-
SMILES
O=C(C1=CC=NC=C1)N/N=C/C2=CNC3=C2C=CC=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Naïve CD4+ T-cell subset differentiation/polarization
Naïve CD4+ T-cell subset differentiation/polarization is an in vitro assay in which purified naïve CD4+ T cells are activated through TCR and CD28 costimulation and cultured with defined cytokines and neutralizing antibodies to generate Th0, Th1, Th2, Th17, or induced Treg-like populations. Differentiation is detected by subset-associated cytokines and transcription factors: IFN-γ/T-bet for Th1, IL-4/GATA3 for Th2, IL-17A/RORγt for Th17, and Foxp3 for induced Treg cells. The assay readout is usually generated by intracellular cytokine staining after restimulation, transcription-factor staining by flow cytometry, ELISA of secreted cytokines, or gene-expression analysis. The result reflects cytokine-directed lineage commitment or polarization rather than antigen-specific immune protection by itself.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)